Barinthus Biotherapeutics plc (FRA:2AB)

Market Cap	22.28M -15.5%
Revenue (ttm)	n/a
Net Income	-56.58M
EPS	-1.40
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.5200
Previous Close	0.5050
Day's Range	0.5200 - 0.5200
52-Week Range	0.4460 - 1.5400
Beta	n/a
RSI	56.93
Earnings Date	May 7, 2026

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 14
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 2AB

Financial Performance

Financial numbers in USD